|
Jul 28
|
BNB Rises Over 6% Amid U.S.-EU Trade Deal and $610M Corporate Buying
|
|
Jul 26
|
BNB Rebounds to $780 After $520M Windtree Buy Commitment, Shows Signs of Stabilizing
|
|
Jul 25
|
Why Are Public Companies Amassing ETH, XRP, SOL, BNB Instead Of Just Bitcoin?
|
|
Jul 22
|
Kraken to Support Biotech Firm Windtree’s $200M BNB Treasury Play
|
|
Jun 26
|
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
|
|
May 6
|
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
|
|
Feb 12
|
Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference
|
|
Oct 9
|
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design
|
|
Jul 25
|
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
|
|
Dec 19
|
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
|
|
Dec 18
|
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
|
|
Aug 7
|
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
|